Primary Sclerosing Cholangitis Market Growth Owing To Increasing Prevalence And Lack Of Cure

0
1K

SWOT Analysis
Strength:
- Increasing research and development activities for developing effective therapeutics is expected to drive the market growth. Several clinical trials are being conducted to evaluate drug candidates.
- Rising awareness regarding primary sclerosing cholangitis is positively impacting the market. Various non-profit organizations are conducting awareness programs.
- Availability of various treatment options such as medications, endoscopic procedures, and liver transplantation provide hope to patients.

Weakness:
- Lack of approved drugs for effective treatment of primary sclerosing cholangitis poses a major challenge. Existing treatment options only manage symptoms.
- High costs associated with liver transplantation limits its widespread adoption in developing regions.

Opportunity:
- Emerging economies presents lucrative growth opportunities owing to increasing healthcare expenditure and large patient population base.
- Ongoing research on developing biomarker-based diagnostic tests is expected to expedite the diagnosis process.

Threats:
- Chronic nature of the disease affects treatment compliance and dropout rates from clinical trials.
- Stringent regulatory process for drug approval delays market accessibility of new treatment options.

Key Takeaways
The Global Primary Sclerosing Cholangitis Market Size is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing research funding initiatives for developing novel therapeutics.

Regional analysis
North America dominated the global market in 2022 and is expected to maintain its lead over the forecast period. This is attributed to growing PSC patient pool coupled with presence of major players in the region. Asia Pacific is anticipated to be the fastest growing market due to rising healthcare expenditure, increase in disease awareness levels.

Key players
Key players operating in the primary sclerosing cholangitis market are Dr. Falk Pharma, Intercept Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson, Takeda Pharmaceutical, HighTide Therapeutics. Dr. Falk Pharma leads the market and has established its Ursodeoxycholic acid capsule brands for PSC symptom management globally.

Read More- https://shortkro.com/north-america-contributes-the-largest-share-of-the-primary-sclerosing-cholangitis-market/ 

Căutare
Categorii
Citeste mai mult
Alte
Carbon Fiber Square Tube Market Revenue, Growth Rate, and Market Entry Barriers
The Global "Carbon Fiber Square Tube Market" Report for 2024–2031 is notable for its...
By Ritu Kumar 2024-11-07 09:38:27 0 132
Alte
Asia Pacific Sports Detergent Market Growth, Top Vendors, Regional Outlook and Forecast by 2031
The Asia Pacific Sports Detergent Market has registered tremendous growth in the past few years....
By Lara Bell 2024-10-10 05:21:19 0 174
Health
Membranous Nephropathy Market Demand, Size, Share, Growth Opportunities, Market Potential, Segmentation, Trends & Global Industry Forecast to 2032
The Membranous Nephropathy Market Size was valued at USD 0.18 billion in 2022 and is projected to...
By Amol Shinde 2024-08-05 06:49:34 0 403
Health
Negative Pressure Wound Therapy Market Size, Share, Growth Analysis 2023
The global negative pressure wound therapy market size was valued at USD 2.6 billion in 2022 and...
By Muthyala Rekha 2023-08-31 07:04:18 0 1K
Alte
The Ultimate Guide to Gaming Accessories
Gaming has evolved from a niche hobby to a global phenomenon. The right gaming accessories can...
By Aula India 2024-07-29 05:39:38 0 537